Article

A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers.

2020-10-05

Abstract excerpt

The management of Parkinson’s disease (PD) is frequently compromised by complications induced by dopaminergic treatment such as involuntary movements (dyskinesias) and psychosis. Mesdopetam (IRL790) is a novel dopamine D3 receptor antagonist developed for the management of complications of therapy in PD. Aim To evaluate safety, tolerability and pharmacokinetics of escalating single and multiple doses of mesdopetam...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2bf593bd-3f9d-532c-bb08-1a5e9716c1dc
DOI: 10.22541/au.160192977.72611929/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers.DOI 10.22541/au.160192977.72611929/v1Read

Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing.Semantic proximity Read

Psychedelic Therapy: A Primer for Primary Care Clinicians—MescalineSemantic proximity Read

Understanding Drug-Induced Movement Disorders: Causes, Symptoms, and TreatmentSemantic proximity Read

The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers.Semantic proximity Read

Istradefylline Safety Profiles: Examination of Individual Case Safety Reports in the FDA Adverse Event Reporting System (FAERS) DatabaseSemantic proximity Read

Safety and tolerability of intravenous liposomal GM1 in patients with Parkinson disease: A single center open-label clinical phase I trial (NEON trial)Semantic proximity Read

KDS2010, a newly developed reversible MAO-B inhibitor, as an effective therapeutic candidate for Parkinson’s diseaseSemantic proximity Read

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of mocravimod in Healthy VolunteersSemantic proximity Read

The pharmacokinetics of pergolide in Parkinson's disease.Semantic proximity Read

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Verify the Efficacy and Safety of Ansofaxine (LY03005) for Major Depressive DisorderSemantic proximity Read

“The Efficacy and Safety of Aripiprazole and Paliperidone 1 and 3-Month Long-Acting Preparations During The Maintenance of Schizophrenia in Clinical Practice”Semantic proximity Read

Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.Semantic proximity Read